23,508 Shares in Innoviva, Inc. (NASDAQ:INVA) Acquired by Nomura Holdings Inc.

Nomura Holdings Inc. bought a new position in Innoviva, Inc. (NASDAQ:INVA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 23,508 shares of the biotechnology company’s stock, valued at approximately $377,000.

A number of other hedge funds also recently bought and sold shares of the company. SummerHaven Investment Management LLC grew its holdings in shares of Innoviva by 1.2% in the fourth quarter. SummerHaven Investment Management LLC now owns 58,298 shares of the biotechnology company’s stock worth $935,000 after purchasing an additional 705 shares during the last quarter. Profund Advisors LLC grew its holdings in Innoviva by 7.9% in the 3rd quarter. Profund Advisors LLC now owns 11,879 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 871 shares during the last quarter. Quadrant Capital Group LLC increased its position in shares of Innoviva by 13.2% in the fourth quarter. Quadrant Capital Group LLC now owns 9,042 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 1,056 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Innoviva by 2.7% during the third quarter. PNC Financial Services Group Inc. now owns 46,109 shares of the biotechnology company’s stock valued at $599,000 after acquiring an additional 1,234 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Innoviva by 14.1% during the fourth quarter. Victory Capital Management Inc. now owns 12,600 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,558 shares during the period. Institutional investors own 99.12% of the company’s stock.

Innoviva Price Performance

Shares of NASDAQ INVA opened at $15.90 on Friday. Innoviva, Inc. has a 1 year low of $12.22 and a 1 year high of $16.86. The stock has a market capitalization of $992.80 million, a P/E ratio of 7.16 and a beta of 0.58. The company’s 50-day moving average is $15.62 and its 200 day moving average is $15.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.42 and a quick ratio of 9.17.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported $0.46 earnings per share for the quarter. Innoviva had a return on equity of 28.94% and a net margin of 58.21%. The firm had revenue of $77.50 million for the quarter. On average, sell-side analysts expect that Innoviva, Inc. will post 1.09 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on INVA shares. Cantor Fitzgerald assumed coverage on Innoviva in a report on Tuesday, June 18th. They set an “overweight” rating on the stock. TheStreet raised Innoviva from a “c” rating to a “b-” rating in a research note on Thursday, February 29th. Finally, StockNews.com raised Innoviva from a “hold” rating to a “buy” rating in a research note on Friday, March 29th.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.